Fig. 1 · Structure
Documents & Downloads
KCC009
TG2 Inhibitor
KCC009 is a selective transglutaminase 2 (TG2) inhibitor known for its ability to induce p53-independent radiosensitization in various cancer types. This compound enhances the efficacy of radiation therapy by modulating intracellular signaling pathways associated with cell survival and apoptosis. KCC009 is essential for research focused on developing novel cancer treatment strategies and exploring the role of TG2 in oncogenesis.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 744198-19-4 |
| Applications | TG2 Inhibitor |
| Formula | C21H22BrN3O5 |
| Molecular Weight | 476.32 |
| SMILES | O=C(N[C@H](C(NCC1CC(Br)=NO1)=O)CC2=CC=C(C=C2)O)OCC3=CC=CC=C3 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.